Van Agthoven M, Heule-Dieleman HA, Knegt PP, Kaanders JH, Baatenburg de Jong RJ, Kremer B, Rene Leemans C, Marres HA, Manni JJ, Langendijk JA, Levendag PC, Tjho-Heslinga RE, De Jong JM, De Boer MF, Uyl-de Groot CA. Compliance and efficiency before and after implementation of a clinical practice guideline for laryngeal carcinomas. Eur Arch Otorhinolaryngol 2006; 263: 729-737.
Anderson BO, Yip CH, Ramsey SD, Bengoa R, Braun S, Fitch M, Groot M, Sancho-Garnier H, Tsu VD; for the Global Summit Health Care Systems and Public Policy Panel. Breast cancer in limited-resource countries: health care systems and public policy. Breast J 2006; 12 Suppl 1: S54-69.
Baltussen R. Priority setting of public spending in developing countries: do not try to do everything for everybody. Health Policy 2006; 78: 149-156.
Baltussen R, Bruce E, Rhodes G, Narh-Bana SA, Agyepong I. Management of mutual health organizations in Ghana. Trop Med Int Health 2006; 11: 654-659.
Baltussen R, Niessen LW. Priority setting of health interventions: the need for multi-criteria decision analysis.Cost Eff Resour Alloc 2006; 4: 14.
Baltussen R, Stolk EA, Chisholm D, Aikins M. Towards a multi-criteria approach for priority setting: an application to Ghana. Health Econ 2006; 15: 689-696.
Baltussen R, Ye Y. Quality of care of modern health services as perceived by users and non-users in Burkina Faso. Int J Qual Health Care 2006; 18: 30-34.
Van den Berg B, Brouwer WBF, Van Exel NJA, Koopmanschap MA, Van den Bos GAM, Rutten FFH. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods.Soc Sci Med 2006; 62: 835-845.
Bleichrodt H, Van Doorslaer E. A welfare economics foundation for health inequality measurement. J Health Econ 2006; 25: 945-957.
Bleichrodt H, Eeckhoudt L. Willingness to pay for reductions in health risks when probabilities are distorted.Health Econ 2006; 15: 211-214.
Boersma C, Radeva JI, Koopmanschap MA, Voors AA, Postma MJ. Economic evaluation of valsartan in patients with chronic heart failure: results from Val-HeFT adapted to the Netherlands. Journal of Medical Economics 2006; 9: 121-131.
Boot HJ, De Melker HE, Stolk EA, De Wit GA, Kimman TG. Assessing the introduction of universal varicella vaccination in the Netherlands. Vaccine 2006; 24: 6288-6299.
Brouwer WBF. Too important to ignore: informal caregivers and other significant others.Pharmacoeconomics 2006; 24: 39-41.
Brouwer WBF, Van Baal PHM, Van Exel NJA. De dubbele prijs van succes: the pain is in the gain. TSG 2006; 84(Bijlage Economie en Volksgezondheid): 7-10.
Brouwer WBF, Calkoen P. Kiezen in de zorg moeilijk maar noodzakelijk. Ned Tijdschr Mondhygiëne 2006; 11: 18-21.
Brouwer WBF, Van Exel NJA, Baltussen RMPM, Rutten FFH. A dollar is a dollar is a dollar – or is it? Value Health 2006; 9: 341-347.
Brouwer WBF, Van Exel NJA, Van Gorp B, Redekop WK. The CarerQol instrument: a new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations. Qual Life Res 2006; 15: 1005-1021.
Brouwer WBF, Van Exel NJA, Schut FT. De markt is geen zorg! TSG 2006; 84: 193-194.
Brouwer WBF, Polder JJ, Van Exel NJA, Van Baal P. Gezond leven niet per se goedkoper. Medisch Contact 2006; 61: 878-881.
Brouwer WBF, Polder JJ, Van Lienden H, Boot JM. Economie is goed voor volksgezondheid en zorg! TSG 2006; 84(Bijlage Economie en Volksgezondheid): 3.
Cohen JP. Cost-effectiveness and resource allocation [letter]. JAMA 2006; 295: 2723.
Cohen JP. Transatlantic convergence with respect to the fourth hurdle? Pharmacoeconomics 2006; 24 Suppl 2: 85-92.
Cohen JP, Cabanilla L, Sosnov J. Role of follow-on drugs and indications on the WHO Essential Drug List. J Clin Pharm Ther 2006; 31: 585-592.
Cohen JP, Cairns C, Paquette C, Faden L. Comparing patient access to pharmaceuticals in the UK and US.Appl Health Econ Health Policy 2006; 5: 177-187.
Dijkers M, Korving K, Van Exel NJA. Wat vindt de huisarts belangrijk tijdens een dienst? Een exploratief onderzoek naar de visie van huisartsen op de kwaliteit van huisartsenposten. Huisarts & Wetenschap 2006; 49: 447-453.
Dijkstra RF, Niessen LW, Braspenning JC, Adang E, Grol RT. Patient-centred and professional-directed implementation strategies for diabetic guidelines: a cluster-randomized trialbased cost-effectiveness analysis. Diabet Med 2006; 23: 164-170.
Van Etten G, Baltussen R, Bijlmakers L, Niessen LW. Advancing the Mexico agenda for health systems research: from clinical efficacy to population health. Trop Med Int Health 2006; 11: 1145-1146.
Van Exel NJA, Brouwer WBF, Van den Berg B, Koopmanschap MA. With a little help from an anchor: discussion and evidence of anchoring effects in contingent valuation. The Journal of Socio-Economics 2006; 35: 836-853.
Van Exel NJA, De Graaf G, Brouwer WBF. “Everyone dies, so you might as well have fun!” Attitudes of Dutch youths about their health lifestyle. Soc Sci Med 2006; 63: 2628-2639.
Van Exel NJA, Koopmanschap MA, McDonnell J, Chapple CR, Berges R, Rutten FFH. Medical consumption and costs during a one-year follow- up of patients with LUTS suggestive of BPH in six European countries: report of the TRIUMPH study. Eur Urol 2006; 49: 92-102.
Van Exel NJA, Morée M, Koopmanschap MA, Schreuder-Goedheijt T, Brouwer WBF. Respijtzorg: een verkenning van behoefte en gebruik onder 273 mantelzorgers. TSG 2006; 84: 90-99.
Van Exel NJA, Morée M, Koopmanschap MA, Schreuder-Goedheijt T, Brouwer WBF. Respite care: an explorative study of demand and use in Dutch informal caregivers. Health Policy 2006; 78: 194-208.
De Graaf G, Brouwer WBF, Van Exel NJA. Gezondheidshoudingen van jongeren in klas 1 en 2 van het voortgezet onderwijs: een Q-methodologische studie. TSG 2006; 84: 215-222.
Groot MT, Baltussen R, Uyl-de Groot CA, Anderson BO, Hortobagyi GN. Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, north america, and Asia. Breast J 2006; 12 Suppl 1: S81-90.
Groot MT, Huijgens PC, Uyl-de Groot CA. Introduction of expensive pharmaceuticals in haematooncology in the Netherlands and throughout Europe. Eur J Hosp Pharm Pract 2006; 12: 30-36.
Groot MT, Ossenkoppele GJ, Reed SD, Huijgens PC, Uyl-de Groot CA. Kosten-effectiviteit van de behandeling van chronisch myeloïde leukemie in het Imatinib tijdperk. Ned Tijdschr Hematol 2006; 3: 93-103.
Hakkaart-van Roijen L, Van Straten A, Al M, Rutten FFH, Donker M. Cost-utility of brief psychological treatment for depression and anxiety. Br J Psychiatry 2006; 188: 323-329.
Herder GJ, Kramer H, Hoekstra OS, Smit EF, Pruim J, Van Tinteren H, Comans EF, Verboom P, Uyl-de Groot CA, Welling A, Paul MA, Boers M, Postmus PE, Teule GJ, Groen HJ. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 2006; 24: 1800-1806.
Hoogendoorn M, Feenstra TL, Rutten-van Mölken MPMH. Toekomstprojecties van het zorggebruik en de kosten van astma en COPD in Nederland. Ned Tijdschr Geneeskd 2006; 150: 1243-1250.
Hoogendoorn M, Feenstra TL, Schermer TRJ, Hesselink AE, Rutten-van Mölken MPMH. Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice. Resp Med 2006; 100: 83-86.
Hoogendoorn M, Rutten-van Mölken MPMH, Feenstra TL. Author reply to comments on ‘A dynamic population model of disease progression in COPD’. Eur Respir J 2006; 27: 241-242.
Van Ineveld BM, Dohmen P, Redekop WK. De startende marktwerking in de gezondheidszorg. ESB 2006; 91: 470-473.
Kamphuis S, Nieboer A, Van Exel NJA. De slag om de verzekerde: concurrentie speelt ondergeschikte rol bij samenstelling aanvullende pakket. Medisch Contact 2006; 61: 143-145.
Korthals-de Bos IBC, Gerritsen AAM, Van Tulder MW, Rutten-van Mölken MPMH, Ader HJ, De Vet HCW, Bouter LM. Surgery is more cost-effective than splinting for carpal tunnel syndrome in the Netherlands: results of an economic evaluation alongside a randomized controlled trial. BMC Musculoskelet Disord 2006; 7: 86.
Krol M, Brouwer WBF, Sendi P. Productivity costs in health-state valuations: does explicit instruction matter?Pharmacoeconomics 2006; 24: 401-414.
Lamers LM, Bouwmans CAM, Van Straten A, Donker MCH, Hakkaart-van Roijen L. Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Econ 2006; 15: 1229-1236.
Lamers LM, McDonnell J, Stalmeier PFM, Krabbe PFM, Busschbach JJV. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006; 15: 1121-1132.
Lamers LM, Stalmeier PFM, Krabbe PFM, Busschbach JJV. Inconsistencies in TTO and VAS values for EQ-5D health states. Med Decis Making 2006; 26: 173-181.
Van der Maas ICS, Brouwer WBF, Van Exel NJA. Zorg in eigen regie, of liever niet? Houdingen onder mensen van 55 jaar en ouder ten aanzien van het PgB als alternatief voor zorg in natura. TSG 2006; 84: 394-402.
Niezen MGH, Stolk EA, Steenhoek A, Uyl-de Groot CA. Inequalities in oncology care: economic consequences of high cost drugs. Eur J Cancer 2006; 42: 2887-2892.
Van Nooten F, Van Agthoven M. DBC’s: visies en verwachtingen van het veld. ZM Magazine 2006; 22: 10-13.
Nuijten MJC, Poulsen Nautrup B, Liedgens H. Oral fixed drug combination analgesic tramadol/paracetamol: benefits for patients and budgets. Expert Review of Pharmacoeconomics & Outcomes Research 2006; 6: 113-121.
Oostenbrink JB, Rutten FFH. Cost assessment and price setting of inpatient care in the Netherlands: the DBC case-mix system. Health Care Manag Sci 2006; 9: 287-294.
Redekop WK. Cost-effectiveness analyses of diagnostic strategies: a literature survey using the NHS Economic Evaluation Database. Expert Review of Pharmacoeconomics & Outcomes Research 2006; 6: 41-48.
Rutten-van Mölken MPMH, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 630-634.
Rutten-van Mölken MPMH, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006; 130: 1117-1128.
Shrestha N, Samir KC, Baltussen R, Kafle KK, Bishai D, Niessen LW. Practical approach to lung health in Nepal: better prescribing and reduction of cost. Trop Med Int Health 2006; 11: 765-772.
Smit F, Cuijpers P, Oostenbrink JB, Batelaan N, De Graaf R, Beekman A. Costs of nine common mental disorders: implications for curative and preventive psychiatry. J Ment Health Policy Econ 2006; 9: 193-200.
Smit F, Willemse G, Koopmanschap MA, Onrust S, Cuijpers P, Beekman A. Cost-effectiveness of preventing depression in primary care patients: randomised trial. Br J Psychiatry 2006; 188: 330-336.
Uyl-de Groot CA. Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer care. Eur J Cancer 2006; 42: 2862-2866.
Uyl-de Groot CA, McDonnell J, Ten Velde G, Radice D, Groen HJM. Cost-effectiveness of hypothetical new cancer drugs in patients with advanced small-lung cancer: results of a Markov chain model. Therapeutics and Clininal Risk Management 2006; 2: 317-323.
Visser JJ, Van Sambeek MRHM, Hunink MGM, Redekop WK, Van Dijk LC, Hendriks JM, Bosch JL. Acute abdominal aortic aneurysms: cost analysis of endovascular repair and open surgery in hemodynamically stable patients with 1-year follow-up. Radiology 2006; 240: 681-689.
Van Wijngaarden JDH, Dirks M, Dippel DWJ, Minkman M, Niessen LW. Towards effective and efficient care pathways: thrombolysis in acute ischaemic stroke. QJM 2006; 99: 267-272.